Stockholders Approve 850,000 Share Increase for Equity Incentive Plan
IMA sits 44% above its 52-week low of $3.94.
Summary
ImageneBio stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing the share reserve by 850,000 shares, which could lead to significant future dilution.
Key Events · Corporate Governance and Compliance · IMA
-
Equity Incentive Plan Amended
Stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing the aggregate number of shares authorized for issuance under the plan by 850,000 shares. This also includes shares issuable upon conversion or exercise of convertible preferred stock and prefunded warrants in the calculation of the annual automatic share reserve increase.
-
Potential Dilution
Based on 11,279,130 outstanding shares as of April 28, 2026, the additional 850,000 authorized shares represent a potential dilution of approximately 7.53% if all were issued.
-
Routine Governance Matters Approved
Stockholders also elected two Class II directors (David P. Bonita, M.D. and Joseph P. Slattery) and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
Analysis · IMA · Life Sciences
ImageneBio's stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing the shares authorized for issuance by 850,000. This authorization, if fully utilized, represents a potential dilution of approximately 7.53% to existing shareholders. While necessary for attracting and retaining talent, this adds to the dilutive impact following the company's recent $30 million private placement in April, which also involved significant equity issuance.
At the time of this filing, IMA was trading at $5.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.2M. The 52-week trading range was $3.94 to $213.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.